Clearside Biomedical Inc (CLSD) concluded trading on Thursday at a closing price of $0.6, with 3.76 million shares of worth about $2.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -34.59% during that period and on July 17, 2025 the price saw a loss of about -28.01%. Currently the company’s common shares owned by public are about 77.27M shares, out of which, 61.36M shares are available for trading.
Stock saw a price change of -31.26% in past 5 days and over the past one month there was a price change of -24.44%. Year-to-date (YTD), CLSD shares are showing a performance of -51.47% which decreased to -36.65% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.70 but also hit the highest price of $1.65 during that period. The average intraday trading volume for Clearside Biomedical Inc shares is 234.03K. The stock is currently trading -26.14% below its 20-day simple moving average (SMA20), while that difference is down -26.53% for SMA50 and it goes to -37.01% lower than SMA200.
Clearside Biomedical Inc (NASDAQ: CLSD) currently have 77.27M outstanding shares and institutions hold larger chunk of about 13.28% of that.
The stock has a current market capitalization of $46.77M and its 3Y-monthly beta is at 2.12. It has posted earnings per share of -$0.41 in the same period. It has Quick Ratio of 3.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLSD, volatility over the week remained 37.76% while standing at 12.77% over the month.
Stock’s fiscal year EPS is expected to rise by 32.52% while it is estimated to increase by 4.95% in next year. EPS is likely to grow at an annualized rate of 23.71% for next 5-years, compared to annual growth of 10.40% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Chardan Capital Markets on August 21, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by Oppenheimer stated Clearside Biomedical Inc (CLSD) stock as an Outperform in their note to investors on June 25, 2024, suggesting a price target of $5 for the stock. On December 15, 2021, Wedbush Resumed their recommendations, while on July 29, 2021, H.C. Wainwright Initiated their ratings for the stock with a price target of $10. Stock get a Buy rating from ROTH Capital on May 13, 2020.
